All In Biotech

Drug Trial Radar · NCT05737784

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 13, 2023

Primary completion

Apr 1, 2026

Study completion Feb 2028

Sponsor

Lead sponsor
Praxis Precision MedicinesIndustry
Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.

Conditions

  • SCN2A-DEE
  • Epilepsy

Interventions

  • PRAX-222 - Initial DoseDrug

    PRAX-222

  • PRAX-222 - Initial Ascending DosesDrug

    Ascending doses of PRAX-222

  • PRAX-222 - Optional Ascending DosesDrug

    Escalation of PRAX-222 dose(s)

  • PRAX-222 - Fixed DosesDrug

    Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222

  • PlaceboProcedure

    Placebo procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation)Time frame: Screening (-8 weeks) through up to 92 weeks
  2. Seizure frequency (Confirmatory Phase)Time frame: 36 to 40 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Le Bonheur Childrens Hospital

    Memphis, Tennessee

  • Praxis Research Site

    São Paulo, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.